Intravenous Iron in Heart Failure Patients With Iron Deficiency: A Meta‐Analysis of Randomized Controlled Trials
Journal of Evidence-Based Medicine · 2025
DOI: 10.1111/jebm.70057 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Evidence-Based Medicine, 2025. Verfasst von Yangguang Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Eighth Affiliated Hospital, Southern Medical University (The First People's Hospital of Shunde, Foshan), Foshan, China. Hauptthemen laut MEDLINE: Heart Failure, Iron, Anemia, Iron-Deficiency. Die Arbeit nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, The Guangdong Basic and Applied Basic Research Fund, Guangzhou Science and Technology Plan Project.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
The impact of intravenous iron therapy in heart failure (HF) patients with iron deficiency (ID) is still controversial.
Method
We performed an extensive search of electronic databases for pertinent studies, encompassing all records up to March 4, 2024. Using random‐effects models in a meta‐analysis, the collected outcomes data were then synthesized and analyzed.
Result
Fourteen trials with 7786 participants (iron therapy: n = 3994; control: n = 3792) were included. Intravenous iron therapy can decrease the risk of composite events of total hospitalization for HF and cardiovascular (CV) death (RR = 0.82 [0.72, 0.92]), total hospitalization for HF (RR = 0.78 [0.66, 0.91]), first hospitalization for HF and CV death (OR = 0.78 [0.65, 0.93]), CV death (OR = 0.86 [0.76, 0.98]), first hospitalization for HF(OR = 0.77 [0.61, 0.99]), but not significantly reduce the risk of all‐cause mortality (OR = 0.93 [0.83, 1.04]). Furthermore, intravenous iron treatment can improve the distance of 6‐min walking test (6MWT) (WMD = 18.99 [7.41, 30.57]). Subgroup analyses found that intravenous iron may be more beneficial in HF patients with transferrin saturation (TSAT)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The Eighth Affiliated Hospital, Southern Medical University (The First People's Hospital of Shunde, Foshan), Foshan, China.
- Department of Cardiology, the Lecong Hospital of Shunde, Foshan, China.
- Faculty of Medicine, The George Institute For Global Health, University of New South Wales, Sydney, Australia.
ORCID-Profile: Yuli Huang
Förderung
- National Natural Science Foundation of China
- The Guangdong Basic and Applied Basic Research Fund
- Guangzhou Science and Technology Plan Project
- The Scientific Research Start Plan of the Eighth Affiliated Hospital, Southern Medical University
- The Clinical Research Startup Program of the Eighth Affiliated Hospital, Southern Medical University
- Science and Technology Innovation Project from Foshan, Guangdong
- The Clinical Research Startup Program of Shunde Hospital, Southern Medical University
Zitieren
APA
Liu, Y., Li, J., Chen, Y., Li, L., Zhao, L., Zhang, X., & Huang, Y. (2025). Intravenous Iron in Heart Failure Patients With Iron Deficiency: A Meta‐Analysis of Randomized Controlled Trials. Journal of Evidence-Based Medicine. https://doi.org/10.1111/jebm.70057
Vancouver
Liu Y, Li J, Chen Y, Li L, Zhao L, Zhang X, et al. Intravenous Iron in Heart Failure Patients With Iron Deficiency: A Meta‐Analysis of Randomized Controlled Trials. Journal of Evidence-Based Medicine. 2025. doi:10.1111/jebm.70057
BibTeX
@article{Liu2025,
author = {Liu, Yangguang and Li, Jiahuan and Chen, Yingwen and Li, Lingxiao and Zhao, Ling and Zhang, Xiaomei and Huang, Yuli},
title = {Intravenous Iron in Heart Failure Patients With Iron Deficiency: A Meta‐Analysis of Randomized Controlled Trials},
journal = {Journal of Evidence-Based Medicine},
year = {2025},
doi = {10.1111/jebm.70057}
}
EUVIMED